Australian (ASX) Stock Market Forum

IPD - ImpediMed Limited

Jump to new
System

System

Joined
27 June 2010
Posts
4,147
Reactions
309
ImpediMed Limited (IPD) develops bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments. These products have a range of potential commercial applications, notably in the assessment and monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness.

http://www.impedimed.com.au
 
Closed today at 28c but the volume as been dropping off the past few days.....

IPDs.gif
 
Just starting on IPD on a hunch from another stock forum.

What is the sentiment surrounding this, and do you think it would be a short or long sell.

Thanks, Superauditor
 
I just came across this stock. If I had been tempted to buy the break, I would rethink after the pullback into the D-box, and definitely wait for the gap to be closed.

IPD n 27-06-17.png
 
pixel said:
I just came across this stock. If I had been tempted to buy the break, I would rethink after the pullback into the D-box, and definitely wait for the gap to be closed.
Click to expand...

It's enjoyed some positive news flow of late (as indicated by the 2 spikes) and it a prime tax loss reversal candidate come July (or around now). I have a starter position although I would be long gone before the gap close.
 
Is the bottom in for ImpediMed? Today the company announced the publication of the first of a number of manuscripts from data obtained from the PREVENT trial.

From the announcement:
The authors from the PREVENT trial concluded that L-Dex® is very sensitive in the assessment of sub-clinical lymph oedema in patients with a history of breast cancer.

The paper also supports the recommendation for an aggressive measurement protocol consisting of an L-Dex® assessment every three months, especially during the first 6 to 12 months post-surgery to facilitate identification of sub-clinical lymph oedema.
Click to expand...

It's been a long ride down from $1.80 to 26c for IPD over the last couple of years. However the last couple of days have seen it bounce back to be currently trading at 40c. Dead cat bounce, or the beginning of a recovery?

big.chart-IPD.gif
 
My Pick this month

Has broken from a long Consolidation/Distribution
It appears to me that Supply is being shaken out
Particularly at the right hand edge

Lots of Red and little Green but price holding and edging higher


COI 61.gif
 
With only looking at the charts for my picks, I have chosen IPD as 1 of my 4 picks in the Tipping Competition for Full CY 2022.
Thought I'd post a quick chart recording my thoughts at this time.
.
There has been a lot of interest over the last 18 months with price and volume increasing and mostly stronger than the XAO over this time. Short term MA now above the Long term MA with price above both.
.
A few hurdles to overcome but can it get a roll on back towards that 2018 level of $0.54 by the end of the year? I don't know but if it does it will be a great return, over 200%

IPD.png
 
From the start of the year IPD dropped roughly 70% in price so those lofty hopes of 0.54 by the end of this year were unfortunately dashed months ago.

Weekly Chart View:
Since the low in July price has moved up and stabilized, volatility (BB) has tightened, we now have a higher low in place and price is now in the upper half of the bollinger bands (just ?).
Are we seeing this down trend finally reversing back to an uptrend? As always time will tell but we need to break through that 0.09 level (top of the BB) first.
I'm running out of time in this Comp (31st Dec) to make big % returns so I'll be really happy if IPD can get back to it's starting point of 0.175. I know, a big ask by the end of the year but lets see :unsure:.

1666648751539.png
 
So, what allowed IPD to go up 100%+ today?

NCCN Guidelines Updated to Recommend Regular Screening for Lymphoedema including
with Bioimpedance Spectroscopy

ImpediMed Limited (ASX.IPD), today announced that the National Comprehensive Cancer Network®
(NCCN®) released a new version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship on 24 March 2023, which now, for the first time, include bioimpedance spectroscopy (BIS).

Key Points
• The NCCN Guidelines® specifically name bioimpedance spectroscopy as an objective measurement tool to identify early signs of lymphoedema.
• The NCCN Guidelines now recommend regular screening for all cancer survivors at risk of lymphoedema.
• The recommendations made by the NCCN Survivorship Panel were Category 2A, which means that there was uniform NCCN consensus for this new recommendation.
• The inclusion of BIS in the NCCN Guidelines will help establish BIS as standard of care and accelerate adoption by Private Payors and Providers.

Screenshot_20230327-172933_CommSec.jpg
 
Quarterly out, and IPD continuing on since last month's news:
Screenshot_20230422-184126_CommSec.jpg


Looking for cash flow positive, as the dynamics tilt and scale builds

Screenshot_20230422-184323_Drive.jpg
 
Top